ResMed (RMD) Competitors $278.78 +6.84 (+2.52%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$279.15 +0.37 (+0.13%) As of 08/1/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. MEDP, EHC, HIMS, BSX, SYK, MDT, BDX, EW, IDXX, and DXCMShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and DexCom (DXCM). These companies are all part of the "medical" sector. ResMed vs. Its Competitors Medpace Encompass Health Hims & Hers Health Boston Scientific Stryker Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom Medpace (NASDAQ:MEDP) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Is MEDP or RMD more profitable? ResMed has a net margin of 27.22% compared to Medpace's net margin of 18.74%. Medpace's return on equity of 67.66% beat ResMed's return on equity.Company Net Margins Return on Equity Return on Assets Medpace18.74% 67.66% 21.86% ResMed 27.22%26.39%19.24% Does the media refer more to MEDP or RMD? In the previous week, Medpace had 2 more articles in the media than ResMed. MarketBeat recorded 43 mentions for Medpace and 41 mentions for ResMed. ResMed's average media sentiment score of 0.99 beat Medpace's score of 0.83 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 25 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 20 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer MEDP or RMD? Medpace currently has a consensus target price of $406.60, suggesting a potential downside of 3.90%. ResMed has a consensus target price of $274.83, suggesting a potential downside of 1.42%. Given ResMed's stronger consensus rating and higher probable upside, analysts plainly believe ResMed is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 3 Sell rating(s) 9 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93ResMed 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73 Which has stronger earnings and valuation, MEDP or RMD? ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedpace$2.11B5.64$404.39M$13.4531.46ResMed$5.15B7.94$1.02B$9.5129.31 Do institutionals & insiders believe in MEDP or RMD? 78.0% of Medpace shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, MEDP or RMD? Medpace has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. SummaryResMed beats Medpace on 9 of the 17 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$39.87B$10.40B$5.48B$20.68BDividend Yield0.76%1.99%4.73%3.67%P/E Ratio29.3118.4228.6729.07Price / Sales7.9429.01373.9066.27Price / Cash29.4722.3135.4522.84Price / Book8.423.478.274.43Net Income$1.02B$234.77M$3.24B$994.22M7 Day Performance1.27%-4.82%-3.69%-3.35%1 Month Performance8.91%1.80%4.33%-2.06%1 Year Performance24.66%-12.51%25.95%10.15% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.4044 of 5 stars$278.78+2.5%$274.83-1.4%+29.9%$39.87B$5.15B29.319,980Trending NewsEarnings ReportDividend IncreaseAnalyst ForecastGap UpMEDPMedpace4.1786 of 5 stars$453.05+1.2%$411.10-9.3%+9.8%$12.73B$2.23B33.685,900Analyst DowngradeInsider TradeEHCEncompass Health4.8827 of 5 stars$107.10-0.5%$131.50+22.8%+16.8%$10.80B$5.37B22.1340,000Upcoming EarningsHIMSHims & Hers Health2.5708 of 5 stars$58.67+1.8%$39.83-32.1%+237.9%$13.13B$1.48B85.031,637Trending NewsUpcoming EarningsInsider TradeGap DownBSXBoston Scientific4.5367 of 5 stars$105.84-0.3%$117.50+11.0%+40.2%$156.58B$18.49B63.0053,000Trending NewsInsider TradeSYKStryker4.9233 of 5 stars$400.43-0.8%$428.55+7.0%+13.6%$152.84B$23.22B54.1153,000Trending NewsEarnings ReportAnalyst ForecastGap DownMDTMedtronic4.5626 of 5 stars$91.99-1.0%$98.19+6.7%+11.0%$117.98B$33.54B25.4195,000Positive NewsBDXBecton, Dickinson and Company4.4435 of 5 stars$183.06-1.2%$219.22+19.8%-25.3%$52.47B$20.18B34.9474,000Positive NewsUpcoming EarningsEWEdwards Lifesciences4.4798 of 5 stars$78.46-1.9%$85.00+8.3%+28.2%$46.02B$5.65B11.2915,800Analyst UpgradeIDXXIDEXX Laboratories3.292 of 5 stars$566.50+0.2%$557.88-1.5%+12.1%$45.56B$3.90B52.3611,000Positive NewsUpcoming EarningsDXCMDexCom4.9727 of 5 stars$89.53+0.6%$98.72+10.3%+12.7%$35.11B$4.03B66.8110,300Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Medpace Competitors Encompass Health Competitors Hims & Hers Health Competitors Boston Scientific Competitors Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors DexCom Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
